Shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) traded up 7.6% on Friday . The company traded as high as $6.37 and last traded at $6.23. 489,282 shares changed hands during trading, a decline of 64% from the average session volume of 1,352,841 shares. The stock had previously closed at $5.79.
Analyst Upgrades and Downgrades
ATYR has been the topic of a number of research reports. Wells Fargo & Company raised their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, June 20th. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research report on Wednesday, June 4th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $20.20.
View Our Latest Research Report on aTyr Pharma
aTyr Pharma Trading Down 4.5%
The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $4.82 and a 200 day simple moving average of $3.94. The company has a market cap of $509.26 million, a price-to-earnings ratio of -7.02 and a beta of 0.89.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts anticipate that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Group One Trading LLC acquired a new position in aTyr Pharma in the 4th quarter valued at about $26,000. Victory Capital Management Inc. purchased a new stake in aTyr Pharma in the 4th quarter valued at about $37,000. Raymond James Financial Inc. purchased a new stake in aTyr Pharma in the 4th quarter valued at about $39,000. XTX Topco Ltd purchased a new stake in aTyr Pharma in the 4th quarter valued at about $40,000. Finally, Two Sigma Advisers LP purchased a new stake in aTyr Pharma in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 61.72% of the company's stock.
About aTyr Pharma
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access